Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 985

1.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
2.

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.

PMID:
21917306
3.

The changes in residual cancer burden after interval debulking surgery are effective in evaluating the response to adjuvant chemotherapy.

Kong L, Li X, Xu Q, Wei L, Wang J, Cui H, Wang S, Zhao Y.

Chemotherapy. 2011;57(3):209-16. doi: 10.1159/000323625. Epub 2011 May 9.

PMID:
21555882
4.

Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.

Bian C, Yao K, Li L, Yi T, Zhao X.

Arch Gynecol Obstet. 2016 Jan;293(1):163-8. doi: 10.1007/s00404-015-3813-z. Epub 2015 Jul 22.

PMID:
26198168
5.

Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?

Worley MJ Jr, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS.

Gynecol Oncol. 2013 Apr;129(1):69-73. doi: 10.1016/j.ygyno.2013.01.012. Epub 2013 Jan 31.

PMID:
23375727
6.

Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.

Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM 2nd, Horowitz NS, del Carmen MG, Schorge JO.

Ann Surg Oncol. 2012 Mar;19(3):959-65. doi: 10.1245/s10434-011-2100-x. Epub 2011 Oct 13.

PMID:
21994038
7.

[Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].

Mu T, Li XP, Wang JL, Wang SJ, Wang Y, Sun XL, Cui H, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 Aug;47(8):566-70. Chinese.

PMID:
23141174
8.

Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.

Muraji M, Sudo T, Iwasaki S, Ueno S, Wakahashi S, Yamaguchi S, Fujiwara K, Nishimura R.

Gynecol Oncol. 2013 Dec;131(3):531-4. doi: 10.1016/j.ygyno.2013.09.030. Epub 2013 Oct 4.

PMID:
24096109
9.

Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.

Chang SJ, Bristow RE, Ryu HS.

Gynecol Oncol. 2012 Sep;126(3):381-6. doi: 10.1016/j.ygyno.2012.05.014. Epub 2012 May 18.

PMID:
22609747
10.

The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.

Onda T, Yoshikawa H, Yasugi T, Matsumoto K, Taketani Y.

Jpn J Clin Oncol. 2010 Jan;40(1):36-41. doi: 10.1093/jjco/hyp127. Epub 2009 Oct 10.

PMID:
19820253
11.

Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?

Solmaz U, Mat E, Dereli ML, Turan V, Peker N, Tosun G, Dogan A, Adiyeke M, Ozdemir A, Gungorduk K, Sanci M, Yildirim Y.

J BUON. 2015 May-Jun;20(3):847-54.

PMID:
26214639
12.

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.

Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS.

Gynecol Oncol. 2013 Apr;129(1):63-8. doi: 10.1016/j.ygyno.2013.01.009. Epub 2013 Jan 18.

PMID:
23337490
13.

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.

Fagotti A, Vizzielli G, Fanfani F, Costantini B, Ferrandina G, Gallotta V, Gueli Alletti S, Tortorella L, Scambia G.

Gynecol Oncol. 2013 Nov;131(2):341-6. doi: 10.1016/j.ygyno.2013.08.005. Epub 2013 Aug 9.

PMID:
23938372
14.

Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?

Markauskas A, Mogensen O, dePont Christensen R, Jensen PT.

Int J Gynecol Cancer. 2014 Oct;24(8):1420-8. doi: 10.1097/IGC.0000000000000241.

PMID:
25180461
15.

TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Zhang GN, Liu H, Huang JM, Wang L, Zhao JS, Li C, Mi K, Zhu Y, Cheng J, Zha X.

Gynecol Oncol. 2014 Mar;132(3):752-7. doi: 10.1016/j.ygyno.2014.01.028. Epub 2014 Jan 23.

PMID:
24463159
16.

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.

Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE.

Gynecol Oncol. 2007 Apr;105(1):211-7. Epub 2007 Jan 18.

PMID:
17239941
17.

Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.

Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D.

J Am Coll Surg. 2003 Dec;197(6):955-63.

PMID:
14644284
18.

Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.

Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E.

Gynecol Oncol. 2008 Jan;108(1):136-40. Epub 2007 Oct 23.

PMID:
17936342
19.

Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.

Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, Saint-Aubert B, Quenet F, Rouanet P, Mollevi C.

Gynecol Oncol. 2014 Nov;135(2):223-30. doi: 10.1016/j.ygyno.2014.09.002. Epub 2014 Sep 16.

PMID:
25220627
20.

Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.

Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.

Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.

PMID:
27916269

Supplemental Content

Support Center